Another sickle cell program stumbles. This time a small molecule

This week might be dubbed “the week of sickle cell disease,” not for its clinical triumphs, but for a series of program discontinuations and disappointments.

Fulcrum Therapeutics Inc. (NASDAQ:FULC) added the latest piece early Friday, when it said FDA placed a full clinical hold on its Phase Ib trial of FTX-6058 in SCD patients due to previously reported preclinical data. The news sent the stock down 56% to $5.66, its lowest close this year, for a loss of $376 million in market cap...